main-image-ataxion-FPO

Ataxion

Ataxion is a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases in partnership with Biogen. Ataxion is leveraging the experience of world-leaders in CNS ion-channel modulators to target novel ion-channels within the central nervous system.

Headquarters Cambridge, MA
Website www.ataxiontherapeutics.com
Pipeline Preclinical
Partnerships Biogen Idec, Saniona